GentiBio closed on a $20 million seed funding led by OrbiMed, Novartis Venture Fund and RA Capital Management. The company also announced exclusive licensing partnerships with Seattle Children’s Research Institute, Benaroya Research Institute at Virginia Mason (BRK), and MIGAL Galilee Research Institute (MIGAL).

With a $30 million investment, Versant Ventures launched Matterhorn Biosciences AG, a company developing T cell receptor therapies based on the recent discovery of MR1-restricted T (MRIT) cells that recognize and kill a wide range of tumors of various tissue origins.

Gene therapy pioneer uniQure launched the first-in-human adeno-associated virus-based gene therapy clinical trial for Huntington’s disease.

A review of recently published scientific studies includes a look at the potential of using flu and pneumonia vaccines to decrease the risk of developing Alzheimer’s disease.

A brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.

The U.S. Food and Drug Administration granted accelerated approval to Gilead Company Kite’s Tecartus (brexucabtagene autoleucel, formerly KTE-X19) as the first approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

A panel of the European Medicines Agency recommended approving GlaxoSmithKline’s experimental treatment for a common form of blood cancer, days after a similar nod from a U.S. Food and Drug Administration panel.

The University of Oxford suggested that the end of 2020 is possible for the availability of a Covid-19 vaccine candidate being developed with AstraZeneca, but expressed caution about the timeline.

Rebecca Vaught never set out to become an entrepreneur, but that’s exactly what happened when she launched Van Heron Labs during 2020 with a goal of reframing the understanding of the body’s organismal and cellular performance.

German biotech firm BioNTech and U.S. drugmaker Pfizer reported additional data showing their experimental Covid-19 vaccine was safe and induced an immune response in patients.